July PBAC winners and losers

While most sponsors received a nod for their new PBS listing submissions considered at the PBAC’s mid-year meet, a number of companies have been left in the dark - at least for the time being.

Pharma in Focus analysis of the reimbursement committee’s July meeting outcomes, published on Friday afternoon, show of the 35 new PBS listing submissions considered, 22 were recommended, five were knocked back, five were deferred, and three were marked ‘not applicable’.

New drugs recommended include Roche’s Columvi in diffuse large B-cell lymphoma, Gilead’s Hepcludex in chronic hepatitis D, Theramex’s Eladynos in osteoporosis, Pharming’s Joenja in activated PI3K delta syndrome, Chiesi’s Elfabrio in Fabry disease, and Ipsen’s Bylvay in progressive familial intrahepatic cholestasis.